Equities Analysts Set Expectations for ADCT FY2025 Earnings

Key Points

• Cantor Fitzgerald has raised its FY2025 earnings per share estimate for ADC Therapeutics to ($1.73), a notable improvement from the previous estimate of ($1.91).
• Guggenheim maintains a "buy" rating with a target price of $10.00, while Royal Bank of Canada downgraded its target price from $8.00 to $5.00, reflecting varied analyst sentiment on the stock.
• ADC Therapeutics' stock recently traded down 1.7% to $3.14, with a market capitalization of $352.69 million and a 12-month range between $1.05 and $3.97.

ADC Therapeutics SA (NYSE:ADCT - Free Report) - Investment analysts at Cantor Fitzgerald increased their FY2025 EPS estimates for shares of ADC Therapeutics in a report released on Wednesday, August 13th. Cantor Fitzgerald analyst E. Schmidt now forecasts that the company will post earnings of ($1.73) per share for the year, up from their prior estimate of ($1.91). The consensus estimate for ADC Therapeutics' current full-year earnings is ($1.69) per share. Cantor Fitzgerald also issued estimates for ADC Therapeutics' FY2026 earnings at ($1.97) EPS.

A number of other brokerages also recently issued reports on ADCT. Wall Street Zen downgraded shares of ADC Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday. Royal Bank Of Canada raised shares of ADC Therapeutics from an "outperform" rating to a "moderate buy" rating and lowered their price target for the stock from $8.00 to $5.00 in a report on Friday, June 20th. Finally, Guggenheim reissued a "buy" rating and issued a $10.00 price target on shares of ADC Therapeutics in a report on Wednesday, August 13th. One investment analyst has rated the stock with a sell rating and four have given a buy rating to the company's stock. Based on data from MarketBeat, ADC Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus price target of $7.75.

ADC Therapeutics Stock Performance

NYSE ADCT traded down $0.06 during trading on Friday, hitting $3.18. 24,165 shares of the company's stock traded hands, compared to its average volume of 586,247. The stock has a market capitalization of $357.75 million, a price-to-earnings ratio of -2.03 and a beta of 1.92. ADC Therapeutics has a 12-month low of $1.05 and a 12-month high of $3.97. The business has a 50 day moving average of $3.01 and a 200-day moving average of $2.18.

ADC Therapeutics (NYSE:ADCT - Get Free Report) last posted its quarterly earnings results on Tuesday, August 12th. The company reported ($0.50) earnings per share for the quarter, missing the consensus estimate of ($0.36) by ($0.14). The company had revenue of $18.84 million for the quarter, compared to the consensus estimate of $17.82 million.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Corient Private Wealth LLC bought a new position in shares of ADC Therapeutics in the second quarter worth approximately $959,000. Bank of America Corp DE increased its position in shares of ADC Therapeutics by 22.1% in the second quarter. Bank of America Corp DE now owns 2,199,059 shares of the company's stock worth $5,893,000 after purchasing an additional 397,905 shares during the last quarter. Nantahala Capital Management LLC bought a new position in shares of ADC Therapeutics in the second quarter worth approximately $6,074,000. Stempoint Capital LP bought a new position in shares of ADC Therapeutics in the second quarter worth approximately $759,000. Finally, Panagora Asset Management Inc. increased its position in shares of ADC Therapeutics by 400.8% in the second quarter. Panagora Asset Management Inc. now owns 271,359 shares of the company's stock worth $727,000 after purchasing an additional 217,173 shares during the last quarter. 41.10% of the stock is currently owned by institutional investors.

About ADC Therapeutics

ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S.